Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person regorafenib [cytosol]

Class:IdChemicalDrug:9657514
_displayNameregorafenib [cytosol]
_timestamp2019-08-08 17:02:34
compartment[Compartment:70101] cytosol
created[InstanceEdit:9657513] Rothfels, Karen, 2019-08-08
crossReference[DatabaseIdentifier:9657515] ChEBI:68647
disease[Disease:1500689] cancer
literatureReference[LiteratureReference:9657442] Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
nameregorafenib
referenceEntity[ReferenceTherapeutic:9657475] regorafenib [Guide to Pharmacology:5891]
stableIdentifier[StableIdentifier:9657516] R-ALL-9657514.1
(hasMember)[CandidateSet:6802559] BRAF inhibitors [cytosol]
[DefinedSet:9669722] type II KIT binding TKIs [cytosol]
[DefinedSet:9674079] type II PDGFR-binding tyrosine kinase inhibitors [cytosol]
(input)[FailedReaction:9669870] Regorafenib-resistant KIT mutants do not bind regorafenib [Homo sapiens]
[FailedReaction:9674408] Regorafenib-resistant PDGFR mutants don't bind regorafenib [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by regorafenib [cytosol] (9657514)